Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
- 31 July 2009
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 45 (11), 1959-1968
- https://doi.org/10.1016/j.ejca.2009.02.011
Abstract
No abstract availableFunding Information
- Pfizer
This publication has 21 references indexed in Scilit:
- Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsJournal of Translational Medicine, 2007
- Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal TumorClinical Cancer Research, 2007
- Sunitinib Induces Hypothyroidism in Advanced Cancer Patients and May Inhibit Thyroid Peroxidase ActivityThyroid®, 2007
- Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI Journal of the National Cancer Institute, 2007
- Angiogenesis Inhibitors and Hypertension: An Emerging IssueJournal of Clinical Oncology, 2006
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to ImatinibJournal of Clinical Oncology, 2005
- Biology of Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000